Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000
Celera Genomics To Present At William Blair Growth Investors Conference June 25
Rockville, MD - June 18, 2003
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that Kathy Ordoņez, President of Celera Genomics and Celera Diagnostics, will present at the William Blair 23rd Annual Growth Stock Conference on Wednesday, June 25, 2003, at 8:30 a.m. CDT at the Four Seasons Hotel in Chicago, Illinois.
The presentation will be webcast and can be accessed by visiting the Celera Genomics Investor Relations web site at www.celera.com. The webcast replay will be available through September 25, 2003.
About Celera Genomics and Applera Corporation
Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets and to discover and develop new therapeutics. Its Celera Discovery SystemTM online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. Celera Diagnostics, a 50/50 jo int venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at www.celera.com.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.
